1027992-86-4

Upstream product

• 1026084-76-3 3-(4-Methyl-6-oxo-2-propyl-1,6-dihydro-pyrimidin-5-yl)-propionic acid ethyl ester 
• 1501-06-0 diethyl 2-acetylglutarate 
• 26177-44-6 4-bromobenzylamine hydrochloride 
• 1027030-09-6 3-(4-Chloro-6-methyl-2-propyl-pyrimidin-5-yl)-propionic acid ethyl ester 

Downstream Products

• 1026334-24-6 8-[2'-(2-tert-Butyl-2H-tetrazol-5-yl)-biphenyl-4-ylmethyl]-4-methyl-2-propyl-5,8-dihydro-6H-pyrido[2,3-d]pyrimidin-7-one 

Relevant academic research and scientific papers

Pyridopyrimidine Angiotensin II Antagonists

A series of pyridopyrimidine angiotensin II (A II) antagonists was synthesized and tested for antagonism of A II. Compounds with a biphenyltetrazole pharmacophore and small alkyl groups at the 2- and 4-positions of the pyridopyrimidine ring were found to be the most potent in an AT1 receptor binding assay and in blocking the A II pressor response in anesthetized, ganglion-blocked A II-infused rats. 5,8-Dihydro-2,4-dimethyl-8--4-yl)methyl>pyridopyrimidin-7(6H)-one (4a) was one of the more potent compounds in the binding assay and was the most efficacious compound in the A II-infused rat model. Further study of 4a in Goldblatt (2K-1C) rats showed the compound to have oral bioavailability and to be an efficacious and potent compound in a high renin form of hypertension.